Loading clinical trials...
Loading clinical trials...
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Conditions
Interventions
Nivolumab
Locations
11
Belgium
University Hospital Leuven
Leuven, Belgium
Thoracic Oncology Centre Munich
Munich, Germany
VUMC
Amsterdam, Netherlands
MAASTRO Clinic
Maastricht, Netherlands
Vall d'Hebron University Hospital
Barcelona, Spain
Catalan Institute of Oncology
Barcelona, Spain
Start Date
November 25, 2015
Primary Completion Date
February 29, 2020
Completion Date
March 31, 2020
Last Updated
August 24, 2022
NCT04585477
NCT07250477
NCT06943820
NCT05713006
NCT06908070
NCT05557552
Lead Sponsor
ETOP IBCSG Partners Foundation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions